Myriad Genetics targets LabCorp with BRCA patent suit

This didn't take long. Myriad Genetics' ($MYGN) attorneys have struck again and filed a suit this time against LabCorp ($LH), barely two days after it launched a series of predictive cancer diagnostic tests focused on BRCA mutations. Genome Web reported that Myriad accuses LabCorp of violating 11 U.S. patents involving its tests that cover BRCA1 and BRCA2 mutations. Myriad has dominated the market, but the U.S. Supreme Court opened the door to competition over the summer with a ruling that invalidated some of its patents but upheld others. With LabCorp's entry into the space, there are now seven rivals marketing tests focused on BRCA mutations, and Myriad is suing all of them. Story (sub. req.)

Suggested Articles

Adaptive Biotechnologies is planning a $200 million IPO to help power its sequencing tests aimed at the body’s immune system and related therapies.

Abbott’s new diabetes test provides A1c results in three minutes, allowing clinicians to develop care plans within a single office visit.

Flatiron has hired a new chief medical officer as it looks to push on under its new parent in the world of electronic health records and real-world data.